Eli Lilly’s donanemab delivers promising Phase 3 data, raising hopes for earlier intervention therapies.
A major Alzheimer’s study released this week confirmed that donanemab, Eli Lilly’s monoclonal antibody, slowed cognitive decline by 35% compared to placebo in early-stage patients. Published in the New England Journal of Medicine, the results bolster optimism following last year’s lecanemab approval.
Donanemab targets amyloid plaques more aggressively, with PET scans showing near-total clearance in 60% of participants within a year. Safety remains a concern: 21% experienced ARIA (brain swelling or microbleeds), though most cases resolved without lasting effects.
Neurologists believe the results mark a turning point in dementia treatment—evidence that targeting pathology earlier yields real functional benefits. Regulators are expected to grant full FDA approval within months. If pricing remains below $30,000 annually, Medicare coverage could make donanemab the most accessible disease-modifying Alzheimer’s therapy to date.